对老年患者使用新型口服抗凝剂的实践安全评价:河南省药物不良反应监测中心的证据
Dexian Ma1, Chen Chen2, Mingyang Sun3
1Center for Drug Reevaluation of Henan, Zhengzhou, People's Republic of China.
Journal of pharmaceutical policy and practice
|September 5, 2025
概括
新的口服抗凝剂 (NOAC),如里瓦洛克萨班和达比加特兰乙酸盐,可能会引起不良反应,主要是出血事件. 加强药物监测和个性化剂量对于安全的临床使用至关重要,特别是在老年患者中.
科学领域:
- 药理学
- 临床药房
- 药物安全
背景情况:
- 新的口服抗凝剂 (NOAC) 越来越多地被处方,但综合性不良反应数据仍然有限.
- 营销后监测对于了解和减轻与NOAC相关的药物不良反应至关重要.
研究的目的:
- 根据现实数据分析和报告与里瓦罗克萨班和达比加特兰乙酸相关的不良反应.
- 确定常见的临床表现,并评估与NOAC相关的副作用的因果关系.
主要方法:
- 在2018年至2023年期间报告的329个NOAC相关的ADR病例的回顾性分析.
- 通过省级食品和药物管理局从医疗机构收集的数据.
- 包括里瓦洛克萨班 (281例) 和达比加特兰 (48例).
主要成果:
- 严重的药物不良反应发生在21. 6%的病例中.
- 常见的副作用包括胃肠道出血,出血,牙出血,凝血障碍和湿疹.
- 在大多数情况下,因果关系评估表明NOAC与严重不良反应之间存在非常可能或可能的关系.
结论:
- 老年患者需要特别注意NOAC的使用.
- 加强药物监测系统对于监测NOAC安全性至关重要.
- 推个性化药物治疗方案以提高临床安全性和合理的药物使用.
相关概念视频
Pharmacovigilance
981
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
981
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
888
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
888
Antihypertensive Drugs: Direct Renin Inhibitors
817
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
817
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
869
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
869


